This research investigates a new inhaled medication called ensifentrine for people with a lung disease called non-cystic fibrosis bronchiectasis (NCFBE). NCFBE is a condition where the airways in the lungs become damaged, leading to mucus buildup and infections. The study lasts for at least 24 weeks, and the main goal is to see if ensifentrine can help reduce lung flare-ups and improve life quality compared to a placebo, which is a harmless substance with no therapeutic effect.

• Participants will inhale the medication or placebo twice daily using a device called a nebulizer, without knowing which they receive.
• To qualify, participants must have a documented history of lung infections and meet specific health criteria.
• The study excludes those with certain health conditions or who use particular medications.

This trial is double-blind, meaning neither the participants nor the researchers know who is receiving the actual medication or the placebo. If you have NCFBE, this study might help you while contributing to important research on new treatments.